To be published in February 2015: Corporate Reputation of Pharma in 2014 – a Patient Perspective, 4th edition

To be published in February 2015:  
Corporate Reputation of Pharma in 2014 – a Patient Perspective, 4th edition

shutterstock_212849056

  • Survey of 1,000 patient groups around the world 
  • Conducted in 12 languages 
      • Indicator I: Whether the company has an effective patient-centred strategy.
      • Indicator II: The quality of the information that the company provides to patients.
      • Indicator III: The company’s record on patient safety.
      • Indicator IV: The usefulness to patients of the company’s products.
      • Indicator V: The company’s record of transparency with external stakeholders.
      • Indicator VI: Whether the company acts with integrity.
  • Companies assessed for 6 indicators  
  • 35 companies scrutinised:  AbbVie l Actavis l Allergan l Amgen l Astellas l AstraZeneca l Baxter International l Bayer l Biogen Idec l Boehringer Ingelheim l Bristol-Myers Squibb l Celgene l Eisai l Eli Lilly (Lilly) l Gilead Sciences l GlaxoSmithKline (GSK) l Grũnenthal l Janssen l Lundbeck l Menarini l Merck & Co (the US company) l Merck Group (the German company) l Mylan l Novartis l Novo Nordisk l Pfizer l Roche l Sanofi l Servier l Shire l Stada Arzneimittel l Takeda l Teva l UCB l ViiV
  • For more information please contact PatientView at report@patient-view, contacts are Clive Nead and Alex Wyke